Akebia Therapeutics Halts Proposed Anemia Trial After FDA Feedback

Akebia Therapeutics will not start its planned trial for Vafseo anemia treatment in non-dialysis kidney disease patients after the FDA requested a larger, costlier study.

Akebia Therapeutics Halts Proposed Anemia Trial After FDA Feedback
Credit: Akebia Therapeutics
Already have an account? Sign in.